Corporate versus Public Interests: Community Responsibility to Defend Scientific Integrity

References

• Gotzsche PC, Kassirer JP, Woolley XL, et al. What should be done to tackle ghostwriting in the medical literature? PLoS Med. Feb 3 2009; 6(2):e23.
   Google Scholar
• Wnukiewicz-Kozlowska A. Legal and ethical aspects of ghostwriting in medicine. Arch Immunol Ther Exp (Warsz). Feb 2011; 59 (1): 1–9.
   PubMed Web of Science ®Google Scholar
• Langdon-Neuner E. Medical Ghost-writing. Mens Sana Monogr. 2008; 6 (1): 257-273.
   Google Scholar
• Flanagin A, Carey LA, Fontanarosa PB, et al. Prevalence of articles with honorary authors and ghost authors in peer-reviewed medical journals. JAMA. Jul 15 1998; 280 (3): 222–224.
   PubMed Web of Science ®Google Scholar
• Mowatt G, Shirran L, Grimshaw JM, et al. Prevalence of honorary and ghost authorship in Cochrane reviews. Jama. Jun 5 2002; 287 (21): 2769–2771.
   PubMed Web of Science ®Google Scholar
• Ross JS, Hill KP, Egilman DS, Krumholz HM. Guest authorship and ghostwriting in publications related to rofe-coxib: a case study of industry docu-ments from rofecoxib litigation. JAMA. Apr 16 2008; 299 (15): 1800–1812.
   PubMed Web of Science ®Google Scholar
• Sismondo S, Nicholson SH. Publication planning 101. J Pharm Pharm Sci. 2009; 12 (3): 273–279.
   PubMed Web of Science ®Google Scholar
• Moffatt B, Elliott C. Ghost marketing: pharmaceutical companies and ghost-written journal articles. Perspect Biol Med. Winter 2007; 50 (1): 18–31.
   PubMed Web of Science ®Google Scholar
• Fugh-Berman AJ, Dodgson S. Ethical considerations of publication planning in the pharmaceutical industry. Open Medicine. 2008;2(4).
   Google Scholar
• Nahai E Ghostwriting: stringent disclosure policies take aim at authorship abuses. Aesthet Surg J. Mar 2010; 30 (2): 265-266.
   Google Scholar
• Eaton L. Medical editors issue guidance on ghost writing. Bmj. Apr 30 2005;330 (7498): 988.
   PubMedGoogle Scholar
• Carey TS, Williams JW, Jr., Oldham JM, et al. Gabapentin in the treatment of mental illness: the echo chamber of the case series. J Psychiatr Pract. Mar 2008; 14 Suppl 1: 15–27.
   PubMed Web of Science ®Google Scholar
• Williams JW, Jr., Ranney L, Morgan LC, Whitener L. How reviews covered the unfolding scientific story of gabapentin for bipolar disorder. Gen Hosp Psychi-atry. May-Jun 2009; 31 (3): 279–287.
   PubMed Web of Science ®Google Scholar
• Ziemba KS, O'Carroll CB, Drazkowski JF, et al. Do antiepileptic drugs increase the risk of suicidality in adult patients with epilepsy?: A critically appraised topic. Neurologist. Sep 2010; 16 (5): 325–328.
   PubMed Web of Science ®Google Scholar
• Fullerton CA, Busch AB, Frank RG. The rise and fall of gabapentin for bipolar disorder: A case study on off-label pharmaceutical diffusion. Med Care. Apr 2010; 48 (4): 372–379.
   PubMed Web of Science ®Google Scholar
• Appendix A-2008 Financial Report. In: Pfizer, ed2008.
   Google Scholar
• Baethge C. On ghost authorship and reviews: the 6th International Congress on Peer Review and Biomedical Publi-cation. Dtsch Arztebl Int. Nov 2009; 106 (45): 731–732.
   PubMed Web of Science ®Google Scholar
• Sismondo S. Ghost management: how much of the medical literature is shaped behind the scenes by the phar-maceutical industry? PLoS Med. Sep 2007;4(9):e286.
   Google Scholar
• Quan SE Guests and ghosts begone-guest authorship and ghostwriting and the Journal of Clinical Sleep Medicine. J Clin Sleep Med. Jun 15 2008;4 (3): 203.
   PubMed Web of Science ®Google Scholar
• Barbour V. How ghost-writing threat-ens the credibility of medical knowledge and medical journals. Haemato-logica. Jan; 95 (1): 1–2.
   Google Scholar
• Ghostwriting: the dirty little secret of medical publishing that just got bigger. PLoS Med. Sep 2009;6(9):e1000156.
   Google Scholar
• (ICMJE) ICoMJE. Uniform Requirements for Manuscripts Submitted to Biomedical Journals. Phildelphia, PA: ICMJE 2007.
   Google Scholar
• Ghost writing initiated by commercial companies. J Gen Intern Med. Jun 2005; 20 (6): 549.
   Google Scholar
• Bosch X. Treat ghostwriting as misconduct. Nature. Jan 27 2011;469(7331): 472.
   PubMed Web of Science ®Google Scholar
• Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med. Nov 23 2000; 343 (21): 1520-1528, 1522 p. following 1528.
   Google Scholar
• Bombardier C, Laine L, Burgos-Vargas R, et al. Response to expression of concern regarding VIGOR study. N Engl J Med. Mar 16 2006; 354 (11): 1196–1199.
   PubMed Web of Science ®Google Scholar
• Abel B. Re: Comments about the new NEJM.org. In: Egilman D S, ed 2011.
   Google Scholar
• Medicine NEJo. Comparison of Upper Gastrointestinal Toxicity of Rofecoxib and Naproxen in Patients with Rheumatoid Arthritis. [Accessed Febru-ary 20, 2011.] Available at: http://www.nejm.org/doi/ful1/10.1056/NEJM200011233432103..
   Google Scholar
• McHenry LB, Jureidini JN. Industry-sponsored ghostwriting in clinical trial reporting: a case study. Account Res. Jul-Sep 2008; 15 (3): 152–167.
   PubMed Web of Science ®Google Scholar
• Jureidini JN, McHenry LB. Conflicted medical journals and the failure of trust. Account Res. Jan 2011;18 (1): 45–54.
   PubMed Web of Science ®Google Scholar
• Thal LJ, Ferris SH, Kirby L, et al. A ran-domized, double-blind, study of rofecoxib in patients with mild cognitive impairment. Neuropsychopharmacol-ogy. Jun 2005; 30 (6): 1204–1215.
   PubMed Web of Science ®Google Scholar
• Psaty BM, Kronmal RA. Reporting mortality findings in trials of rofecoxib for Alzheimer disease or cognitive impairment: a case study based on documents from rofecoxib litigation. Jama. Apr 16 2008; 299 (15): 1813–1817.
   PubMed Web of Science ®Google Scholar
• Newman M. The rules of retraction. Bmj.341:c6985.
   Google Scholar
• Murray S, Brophy J, Palepu A. Open Medicine's ghost and guest authorship policy. 2010.
   Google Scholar
• Statistical review and evaluation: Antiepileptic drugs and suicidality. Office of Biostatistics, Office of Trans-lational Services, Center for Drug Evaluation and Research, Food and Drug Administration, US Department of Health and Human Services; 2008 May 23. Available from: http://www.fda.gov/ohrms/dockets/ac/08/briefing/2008-4372b1-01-FDA.pdf. Accessed March 8, 2011.
   Google Scholar
• Jureidini J, McHenry L, Mansfield P. Clinical trials and drug promotion: selective reporting of study 329. Inter-national Journal of Risk and Safety in Medicine. 2008;20 (1): 8.
   Google Scholar
• Ross JS, Madigan D, Hill KP, Egilman DS, Wang Y, Krumholz HM. Pooled analysis of rofecoxib placebo-con-trolled clinical trial data: lessons for postmarket pharmaceutical safety surveillance. Arch Intern Med. Nov 23 2009;169(21) :1976–1985.
   PubMed Web of Science ®Google Scholar
• Ross JS, Madigan D, Konstam MA, Egilman DS, Krumholz HM. Persis-tence of cardiovascular risk after rofe-coxib discontinuation. Arch Intern Med. Dec 13 2010; 170 (22): 2035–2036.
   PubMedGoogle Scholar
• Egilman D, Presler A. Report of specific cardiovascular outcomes of the ADVANTAGE trial. Ann Intern Med. 2006;144 (16): 1.
   PubMedGoogle Scholar
• Krumholz HM, Ross JS, Presler AH, Egilman DS. What have we learnt from Vioxx? Bmj. Jan 20 2007;334 (7585): 120–123.
   Google Scholar
• Ross JS, Hill KP, Egilman DS, Krumholz HM. Guest authorship and ghostwriting in publications related to rofe-coxib: a case study of industry docu-ments from rofecoxib litigation. JAMA. Apr 16 2008; 299 (15): 1800–1812.
   PubMed Web of Science ®Google Scholar
• Lundh A, Barbateskovic M, Hrobjartsson A, Gotzsche PC. Conflicts of interest at medicaljournals: the influence of industry-supported randomised trials on journal impact factors and revenue-cohort study. PLoS Med.7(10): e1000354.
   Google Scholar
• Anekwe TD. Profits and plagiarism: the case of medical ghostwriting. Bioethics. Jul 2010; 24 (6): 267–272.
   PubMed Web of Science ®Google Scholar
• Hill KP, Ross JS, Egilman DS, Krumholz HM. The ADVANTAGE seeding trial: a review of internal documents. Ann Intern Med. Aug 19 2008;149 (4): 251–258.
   PubMed Web of Science ®Google Scholar
• Thomas L. Judge Rules Drug Documents Must Be Returned to Eli Lilly. The New York Times. February 14, 2007.
   Google Scholar
• Brandeis LD. What Publicity Can Do. Other People's Money. 1914.
   Google Scholar
• Evans D. Big Pharma &s Crime Spree. Bloomber Markets. December 2009.
   Google Scholar
• Egilman D, Ardolino E. The Pharmaceutical Industry, Disease Industry: A Pescription for Illness and Death. In: H. WW, ed. The bottom line or public health: Tactics corporations use to influence health and health policy and what we can do to counter them. Oxford; New York: Oxford University Press; 2010:xix, 570 p.
   Google Scholar